Article info
PDFElectronic pages
Pharmacogenomics: Social, Ethical, and Clinical Dimensions
Citation
Pharmacogenomics: Social, Ethical, and Clinical Dimensions
Publication history
- First published November 30, 2004.
Online issue publication
April 27, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2004 by the Journal of Medical Ethics
Other content recommended for you
- Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report
- Asymmetry in Scientific Method and Limits to Cross-Disciplinary Dialogue
- Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
- Essential(ist) medicine: promoting social explanations for racial variation in biomedical research
- Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation
- Paediatric pharmacogenomics: an overview
- Fifteen-minute consultation: Pharmacogenomics: a guide for busy clinicians
- The patient who reports a drug allergy
- Introduction to pharmacogenetics
- Evidence used in model-based economic evaluations for evaluating pharmacogenetic and pharmacogenomic tests: a systematic review protocol